Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2014, Article ID 743181, 6 pages
http://dx.doi.org/10.1155/2014/743181
Clinical Study

Predictors of Venous Thromboembolic Events Associated with Central Venous Port Insertion in Cancer Patients

1Department of Medical Oncology, Hôpital Cantonal de Fribourg, Chemin des Pensionnats 2, 1700 Fribourg, Switzerland
2Department of Angiology, Hôpital Cantonal de Fribourg, Chemin des Pensionnats 2, 1700 Fribourg, Switzerland
3Central Laboratory, Hôpital Cantonal de Fribourg, Chemin des Pensionnats 2, 1700 Fribourg, Switzerland
4Pharmacy Unit, Hôpital Cantonal de Fribourg, Chemin des Pensionnats 2, 1700 Fribourg, Switzerland

Received 29 August 2013; Revised 2 December 2013; Accepted 16 December 2013; Published 9 February 2014

Academic Editor: Bruno Vincenzi

Copyright © 2014 Christine Hohl Moinat et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Insertion of central venous port (CVP) catheter in the cancer population is associated with increased incidence of venous thromboembolic events (VTE). However, trials have shown limited benefit of antithrombotic treatment to prevent catheter-related venous thrombosis. This prospective observational cohort study was designed to assess the incidence of VTE closely related to CVP implantation in patients with cancer and undergoing chemotherapy, and to identify a high risk subgroup of patients. Between February 2006 and December 2011, 1097 consecutive cancer patients with first CVP implantation were included. Catheter-related VTE were defined as deep venous thrombosis in the arm, with or without pulmonary embolism (PE), or isolated PE. The incidence of CVP-associated VTE was 5.9% (IC95 4.4–7.3%) at 3 months, and 11.3% (IC95 9.4–13.2%) at 12 months. The incidence of any VTE was 7.6% (IC95 6.0–9.3%) at 3 months, and 15.3% (IC95 13.1–17.6%) at 12 months. High Khorana risk score and lung cancer were significant predictors of 3 month VTE. In conclusion, this large cohort study of patients with first CVP catheter implantation confirms the high incidence of VTE associated with the CVP implantation and allow identifying high risk patients who may benefit from thromboprophylaxis.